Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

HER2-enriched breast cancers within the HER2-positive subtype are addicted to the HER2 pathway. Here, the authors analyse gene expression before, during, and after treatment with anti-HER2-based therapies in the phase II PAMELA clinical trial, finding phenotypic changes induced by treatment.

Guardado en:
Detalles Bibliográficos
Autores principales: Fara Brasó-Maristany, Gaia Griguolo, Tomás Pascual, Laia Paré, Paolo Nuciforo, Antonio Llombart-Cussac, Begoña Bermejo, Mafalda Oliveira, Serafín Morales, Noelia Martínez, Maria Vidal, Barbara Adamo, Olga Martínez, Sonia Pernas, Rafael López, Montserrat Muñoz, Núria Chic, Patricia Galván, Isabel Garau, Luis Manso, Jesús Alarcón, Eduardo Martínez, Sara Gregorio, Roger R. Gomis, Patricia Villagrasa, Javier Cortés, Eva Ciruelos, Aleix Prat
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/76ae9021acef4670a550a57d2950a303
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:HER2-enriched breast cancers within the HER2-positive subtype are addicted to the HER2 pathway. Here, the authors analyse gene expression before, during, and after treatment with anti-HER2-based therapies in the phase II PAMELA clinical trial, finding phenotypic changes induced by treatment.

Ejemplares similares